FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Panels to Discuss Ortho Evra and Blood Clot Risks

[ Price : $8.95]

Federal Register Notice: FDAs Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Co...

Correction Made to Withdrawal Notice

[ Price : $8.95]

Federal Register Notice: FDA adds an omitted footnote to a Federal Register notice that withdrew approval of 27 NDAs and 58 ANDAs.

FDA Regulatory Bias on 'Fasting State' with Cancer Drugs?

[ Price : $8.95]

A Journal of Clinical Oncology commentary criticizes an alleged FDA regulatory bias against requiring cancer-treating drugs to be...

FDA Study Finds Maternal BPA Safe for Rat Fetuses

[ Price : $8.95]

A new FDA study finds no detectable levels of the suspected mutagen bisphenol A in the fetuses of pregnant rats orally administere...

Attorney Sees Continuing Off-label Marketing Confusion

[ Price : $8.95]

Attorney John Fleder highlights continuing confusion that exists over FDAs position on off-label drug promotion.

Risk Signals Found in 10 Drugs in 2nd Quarter

[ Price : $8.95]

FDA says that in the second quarter of 2011 it identified potential safety signals in 10 drugs.

Preemption Law, Applications Reviewed

[ Price : $8.95]

Attorney Arnie Friede says FDA and the courts have made differing interpretations of federal preemption law depending on the drug,...

FDA Clears Iris 510(k) Prognostic Prostate Cancer Test

[ Price : $8.95]

FDA clears an Iris International 510(k) for its NADiA ProsVue prognostic cancer test for identifying patients at reduced risk for ...

FDA Places Partial Hold on Immunomedics Trial

[ Price : $8.95]

FDA places a partial clinical hold on Immunomedics Phase 2B/2 clivatuzumab tetraxetan trial for pancreatic cancer.

FDA Says CFC Inhalers Out by 12/31

[ Price : $8.95]

FDA cautions that Primatene Mist will no longer be available as an OTC epinephrine inhaler after 12/31.